DoD Gulf War Illness, Clinical Evaluation Award | W81XWH 21 GWIRP CEA

FY21 DoD Gulf War Illness Research Program (GWIRP) Clinical Evaluation Award - FAQs

1) What is the purpose of the FY21 GWIRP Clinical Evaluation Award?

This award is intended to move the most credible Gulf War Illness (GWI) research findings into clinical studies that directly involve Gulf War Veterans. The focus is on translating validated, objective findings (including qualified and replicated preclinical results) into appropriately designed clinical evaluations.

2) What stage of the GWIRP research pipeline does this award support?

This mechanism sits in the program's "Verification" phase. The goal is to confirm that proposed biomarkers or interventions remain reliable when tested in rigorous clinical evaluations and are ready to inform larger, later-stage clinical trials.

3) What kinds of studies does the solicitation encourage?

The solicitation highlights two main study types:

• Statistically powered biomarker trials to validate biomarkers for use as clinical endpoints.
• Proof-of-concept intervention trials, including pilot studies, first-in-human efforts, and early phase trials (phase 1 through phase 2a).

4) Are projects required to be clinical and statistically meaningful?

Yes. Projects supported under this mechanism are expected to be clinical in nature and statistically meaningful.

5) What types of interventions can be tested in clinical trials under this award?

Clinical trials may evaluate a range of approaches, including pharmacologic agents (drugs or biologics), devices, clinical guidance, and other technologies, as long as there is strong objective evidence supporting the approach in the context of GWI.

6) Can repurposed treatments from other conditions be proposed?

Yes. Repurposed treatments from other conditions that share symptom overlap with GWI may be proposed. However, the program signals a preference for projects that translate qualified findings generated within the GWI research community rather than relying primarily on analogies to other disorders.

7) What additional expectations apply to biomarker-focused applications?

Biomarker applications are expected to expand preliminary findings in a sufficiently large GWI cohort to produce statistically meaningful results. The intended outcome should be biomarker validation that enables the biomarker to function as a clinical endpoint in later, larger-scale trials (phase 2b to phase 3).

8) Must the research be conducted in Gulf War Veterans?

Yes. Across all applications, the research must be conducted in a Gulf War Veteran population.

9) Do applicants need to prove access to study cohorts or key materials?

Yes. Applicants must provide proof that they have access to the necessary cohorts and/or any critical reagents needed to carry out the proposed work.

10) Are preclinical-only projects allowed under this award?

No. Preclinical-only projects are explicitly directed to other GWIRP funding announcements rather than this Clinical Evaluation Award.

11) What are the two optional funding paths, and can an application use both?

There are two optional paths that can increase the maximum allowable direct costs, but they are mutually exclusive. An application may choose one option or neither, but not both.

12) What is the Biorepository Contribution Option (BBRAIN for GWI)?

This option supports applicants who will contribute Gulf War Veteran biospecimens and/or data to the established GWI biorepository network: the Boston Biorepository, Recruitment, and Integrative Network (BBRAIN) for GWI.

13) What is required to qualify for the Biorepository Contribution Option higher funding cap?

To qualify, applicants must submit a Biorepository Contribution Statement with detailed proposed costs and commit to BBRAIN protocols and standard operating procedures to ensure quality and consistency.

14) What is the Clinical Consortium Collaboration Option (GWICTIC)?

This option encourages applicants to leverage the infrastructure of the Gulf War Illness Clinical Trials and Interventions Consortium (GWICTIC). This may include recruitment networks, existing protocols, Common Data Elements, and data management practices.

15) What documentation is required for the GWICTIC collaboration option?

This option requires:

• A letter of commitment or collaboration from GWICTIC describing what services or infrastructure will be shared and how the collaboration adds value to the government.
• A Collaboration Statement detailing costs and commitments to GWICTIC procedures.

16) Why can't an application use both the GWICTIC option and the BBRAIN biorepository option?

Applications using the GWICTIC option cannot also apply under the biorepository contribution option because GWICTIC has its own biospecimen and data policies.

17) What topics or approaches are explicitly not supported?

The solicitation states it will not fund:

• Studies that treat psychiatric disease or psychological stress as the primary cause of Gulf War Illness.
• Projects that implement care guidelines placing major emphasis on psychiatric pathologies or psychiatric remedies.
• Applications focused on amyotrophic lateral sclerosis (ALS) research (as a primary focus).

18) Can a GWI study include Gulf War Veterans who have ALS?

Yes, a study centered on GWI symptomatology may include Gulf War Veterans with ALS if ALS is included within the study's GWI case definition. However, the application cannot be ALS-focused under this opportunity.

19) If an applicant wants to pursue ALS-focused work, where should they look?

The solicitation notes that separate ALS-focused funding is available through the DoD ALS Research Program.

20) What type of award instrument will be used (grant vs cooperative agreement)?

Awards are issued as assistance agreements, meaning they will be made as either a grant or a cooperative agreement depending on how much involvement the Department of Defense anticipates during the work.

21) When would the DoD use a cooperative agreement instead of a grant?

If substantial DoD involvement is expected (for example, active collaboration, participation, or intervention in aspects of the research), the award is typically structured as a cooperative agreement. The specific involvement is described during negotiation.

22) What is the maximum direct cost cap for a standard application?

The anticipated maximum direct costs for the entire period of performance are capped at $1,500,000 for standard applications.

23) What is the maximum direct cost cap under the Biorepository Contribution Option?

The cap increases to $1,520,000 for projects qualifying under the Biorepository Contribution Option.

24) What is the maximum direct cost cap under the Clinical Consortium Collaboration Option?

The cap increases to $1,700,000 for projects qualifying under the Clinical Consortium Collaboration Option.

25) How much total funding was expected for this mechanism, and how many awards?

Program-wide, the DoD expected to allocate about $7.2 million total to fund roughly three awards under this mechanism, subject to federal fund availability, application volume, and scientific and programmatic review outcomes.

26) What were the key dates mentioned for this opportunity?

The opportunity was posted in March 2021 with an original closing date of August 19, 2021. Anticipated awards were to be made no later than September 30, 2022.

27) How long were FY21 funds expected to remain available?

FY21 funds were expected to remain available for use through September 30, 2027.

28) Who is the sponsoring agency for this opportunity?

The sponsoring agency is the Department of Defense, Department of the Army, USAMRAA, under CFDA 12.420.

29) Are eligible applicants restricted by entity type?

Eligible applicants are described as broadly unrestricted by entity type, subject to any additional requirements in the full announcement.

30) What does the solicitation mean by "translation of validated results"?

It means applicants are expected to build on research that has already shown strong, objective evidence in the GWI field. This includes preclinical findings that are qualified and replicated, with the proposed clinical evaluation designed to verify performance in Gulf War Veteran populations.

31) What does the solicitation expect regarding timeline and budget?

Applicants are expected to present a realistic clinical timeline, and budgets are expected to match the phase and scale of the proposed clinical evaluation or trial.